Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BAUSCH & LOMB SUPPORTING CLEAR CHOICE ALCOHOL-FREE MOUTHWASH WITH $15 MIL.

Executive Summary

BAUSCH & LOMB SUPPORTING CLEAR CHOICE ALCOHOL-FREE MOUTHWASH WITH $15 MIL. in consumer and trade ads and promotions focused on consumers looking for a "healthier alternative in mouthwashes." Clear Choice will begin to reach store shelves in October, and Bausch & Lomb expects the product to reach full distribution by December. TV and print ads are slated to break in January. Bausch & Lomb said "surveys of dental professionals and consumers show that both groups will favor a mouthwash which is effective in killing germs and freshening breath without the alcohol content that is characteristic of the mouthwashes on the market today." Noting that "leading brands of mouthwash contain up to 27% alcohol," the company said "this high alcohol level is not necessary to kill germs that cause bad breath -- it is used primarily as a dissolving agent." Package labeling for Clear Choice states: "Fresh Breath Guaranteed," "0% Alcohol/Compare!," "Clear Mint" and "The Alcohol-Free Mouthwash." Bausch & Lomb's promotional materials for Clear Choice cite a 1991 National Cancer Institute study, "Mouthwash Use and Oral Conditions in the Risk of Oral and Pharyngeal Cancer," which, the firm said, "questioned whether alcohol could be attributed to oral cancer." "Although results are inconclusive," the company noted, "it is something of which consumers should be aware." The NCI study found an increased risk of oral cancer associated with the use of mouthwashes with an alcohol content of 25% or higher. In July 29 comments to FDA, the Nonprescription Drug Manufacturers Association asserted that there were "inconsistencies" and "major deficiencies" in the studies and argued that a reanalysis of the NCI study "leads to the conclusion that mouthwash use does not increase the subsequent risk of developing oral cancer" ("The Pink Sheet" Aug. 10, T&G-10). Clear Choice contains Tri-Med, a combination of domiphen bromide, poloxamer and cetylpyridinium chloride. The product "has proven effective at killing germs and fighting bad breath," Bausch & Lomb said. Other ingredients include purified water, glycerin, sodium phosphate, sodium saccharine and mint flavoring. The 16 oz. bottle has a suggested retail price of $2.99.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

Latest Headlines
See All
UsernamePublicRestriction

Register

PS021507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel